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Abstract Background:The POTENT trial compared the safety and efficacy of tipranavir/
ritonavir (TPV/r) to darunavir/ritonavir (DRV/r), each with an optimized
background regimen (OBR) in triple-class experienced HIV-1-infected patients
with resistance to more than one protease inhibitor (PI).
Methodology/Principal Findings: POTENT was a prospective, open-label study
of triple-class (PI, non-nucleoside reverse transcriptase inhibitors [NNRTI], nu-
cleoside reverse transcriptase inhibitors [NRTI]), treatment-experienced, HIV-
positive patients. Subjects were randomized to either TPV/r (500/200mg twice
daily) or DRV/r (600/100mg twice daily) on a genotype-guided, investigator-
selected OBR. CD4+ counts andHIV viral loads were assayed at key timepoints.
The primary endpoint was time to virologic failure (viral load ‡500 copies/mL).
POTENT was prematurely terminated due to slow enrollment. Thirty-nine
patients were treated with either TPV/r (n= 19) or DRV/r (n= 20); 82% were
male, 77%White, with mean age of 43.6 years.Mean baseline HIVRNAwas 3.9
log10 copies/mL.Median prior antiretrovirals was 11, with no prior raltegravir or
maraviroc exposure. Raltegravir was the most common novel class agent in the
OBRs (n= 14TPV/r; n= 12DRV/r). In both groups, patients achievedmean viral
load decreases ‡2 log10 copies/mLbyweek 8, and by week 12mean CD4+ counts
rose by 40–50 cells/mm3. Total observation time was 32 weeks. Drug-related
adverse events were reported in 21% (TPV/r) and 25% (DRV/r) of patients.
Conclusions/Significance: TPV/r- and DRV/r-based regimens showed similar
short-term safety and efficacy. These data support the use of next-generation
PIs such as tipranavir or darunavir with novel class antiretroviral agents
(integrase inhibitors, CCR5 antagonists, or fusion inhibitors).
Trial Registration: Clinicaltrials.gov NCT00517192
Introduction
Drug-resistance presents a major challenge
to the successful long-term management of HIV-
infected treatment-experienced patients. HIV pro-
tease inhibitors (PIs) have been used extensively
since 1996. Due to the structural similarities of
most PIs, emergence of resistance to one PI often
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translated into cross-resistance to other PIs. This
underscores the need for novel, potent PIs with
distinct resistance profiles leading to minimal
cross-resistance to other PIs. Tipranavir (TPV) is a
potent, highly selective, nonpeptidic HIV PI. TPV
plus low-dose ritonavir (TPV/r) [used in combina-
tion with other antiretroviral (ARV) drugs] was
approved by theUSFDA in 2005 for the treatment
of HIV infection among treatment-experienced
patients with PI-resistant virus.[1]
A study of >100 highly PI-resistant clinical
isolates (with a greater than a 10-fold increase in
the concentration that produces 50% inhibition
[IC50] to an average of more than six other PIs)
demonstrated that 90% of these isolates remain
susceptible to TPV. Only 8% and 2% of the iso-
lates were shown to be moderately resistant and
highly resistant, respectively, to TPV.[2] These
laboratory observations have been confirmed in
several clinical trials, including RESIST (Ran-
domized Evaluation of Strategic Intervention in
multidrug reSistant patients with Tipranavir),[3]
Study 1182.51,[4,5] and Study 1182.52,[5] under-
lining the important role that TPV/r plays as a
potent and efficacious treatment option for treat-
ment-experienced patients.
Darunavir (DRV) is the newest PI approved
by the FDA for the treatment of HIV-1 infection,
with accelerated approval in 2006 for use in
PI-resistant, treatment-experienced adults and in
2008 for use in treatment-naı¨ve adults.[6] DRV is
a potent nonpeptidic HIV-1 PI. DRV has been
shown to be an efficacious, safe, and well tolerated
component of ARV regimens for triple-class (PI,
non-nucleoside reverse transcriptase inhibitors
[NNRTI], nucleoside reverse transcriptase inhib-
itors [NRTI]), treatment-experienced patients who
switched regimens in the prospective Darunavir
Outcomes Study,[7,8] and in treatment-experienced
patients undergoing early salvage therapy.[8]
Since multiple mutations in the HIV protease are
generally necessary for the virus to demonstrate
significant resistance to DRV or TPV, these drugs
exhibit a high genetic barrier to the emergence of
novel resistant strains.[9,10]
The POTENT (PrOspecTive EvaluatioN of
Tipranavir vs. Darunavir in Treatment Experienced
Patients) trial compared the safety and efficacy of
TPV/r versusDRVplus low-dose ritonavir (DRV/r)
when each was combined with an optimized back-
ground regimen (OBR) in triple-class-experienced,
HIV-infected patients with resistance to more than
one PI. This head-to-head comparison of these two
PIs in the same patient population was intended
to provide data to help clinicians choose the ap-
propriate ARV therapy for treatment-experienced
patients.
The initial inclusion and exclusion criteria
for patient enrollment in POTENT presented a
challenge to study enrollment, given the avail-
ability of novel therapeutic agents, including ral-
tegravir andmaraviroc, at the time POTENTwas
attempting to recruit patients. Significant efforts
to increase enrollment into the trial, including
relaxing the enrollment criteria, did not result in
improvements in patient recruitment. As a result,
the POTENT trial was prematurely terminated.
While the number of patients included in the trial
and follow-up time are insufficient to draw defin-
itive conclusions, these data provide short-term
virologic and immunologic responseswhen initiating
TPV/r or DRV/r combined with a novel agent such
as raltegravir in this treatment-experienced patient
population. In this brief report, we describe observed
safety and efficacy data of the two study treatment
arms with a focus on the concomitant use of novel
agents as part of the OBR among treatment-
experienced patients with multidrug-resistant HIV.
Methods
Ethics
The research was carried out in compliance with
the POTENT protocol, the principles laid down in
the Declaration of Helsinki (1996 Version), in ac-
cordance with the International Conference on
Harmonization Harmonized Tripartite Guideline
for Good Clinical Practice, and in accordance with
applicable regulatory requirements. Participation
in the POTENT trial was approved by the institu-
tional review board (IRB) of each center involved
in the study. This clinical study enrolled patients
at 56 study sites in ten countries. The complete
names and addresses of the centers (and their
corresponding IRBs) that enrolled patients in the
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POTENT trial can be found in table SI of the
supplemental digital content (SDC), http://links.
adisonline.com/DRZ/A4. Written informed con-
sent was obtained from each patient, or their
legal representative, prior to their participation
in the study. Details of the clinical trial pro-
tocol can be found in the SDC (table SII). The
CONSORT (Consolidated Standards of Report-
ing Trials) checklist can also be found in the SDC
(table SIII).
Objectives
The POTENT study was designed as a ran-
domized, open-label trial to compare the efficacy
and safety of TPV/r (500/200mg twice daily)
with DRV/r (600/100mg twice daily) in HIV-1-
infected patients with triple-class (NRTI, NNRTI,
and PI) treatment experience, who were harbor-
ing virus that was resistant to more than one PI at
screening by virtual phenotype testing. Eligible
patients were randomized to TPV/r or DRV/r,
each combined with an investigator-selected OBR,
with a planned follow-up treatment period of
50 weeks.
Participants
The inclusion criteria consisted of (i) signed
informed consent; (ii) verification of triple-class
treatment history with a minimum of 3 months
duration for each class; (iii) documented viral
resistance to more than one PI; (iv) OBR contain-
ing at least two active agents; (v) plasma viral load
(VL) ‡500copies/mL; and (vi) baseline laboratory
values demonstrating reasonable organ system
function. A CD4+ cell count ‡50 cells/mm3 at
screening was initially required, but this criterion
was removed by a protocol amendment.
Exclusion criteria included (i) prior use of TPV
or DRV; (ii) virtual phenotypic resistance to TPV
or DRV; (iii) female patients who were pregnant,
breastfeeding, or planning to become pregnant;
(iv) patients with unresolved or unstable AIDS-
defining illnesses; (v) active substance abuse; and
(vi) use of agents with contraindications listed in
the product monographs of TPV, DRV, or rito-
navir. Patients who were unresponsive to treatment
(VL decrease <1 log10 copies/mL after 12 weeks
of treatment) or who at or after week 24 had a
VL >400 copies/mL on two consecutive visits (at
least 2 weeks apart) were to be removed from
the study and initiate alternative ARV therapy
in an attempt to establish better control of their
HIV disease.
Description of Procedures or Investigations
Undertaken
The POTENT trial was designed to enroll and
treat 800 HIV-1-infected, antiretroviral-naı¨ve
patients who were to be randomly assigned (1 : 1)
to one of the following open-label treatments:
(i) TPV/r (500/200mg twice daily); or (ii) DRV/r
(600/100mg twice daily). Both agents were ad-
ministered in combination with other available
ARVs selected by the investigator based on pa-
tient history and virtual phenotype screening
results. The randomization lists were prepared by
Boehringer Ingelheim, Inc., in cooperation with
the contractor (Almac Clinical Technologies,
Yardley, PA, USA) of the interactive voice re-
sponse system in an automated fashion using vali-
dated randomization software (RS PMX CTM
version 3.3.0, Rockwell Automation Solution
GmbH, Karlsruhe, Germany). Patient random-
ization was stratified based on their background
regimens, which were sorted according to their
inclusion of zero, one, or two new classes of
agents, and the resistance characteristics of the
patient’s virus to TPV/DRV (sensitive/sensitive,
partially sensitive/sensitive, sensitive/partially sen-
sitive, partially sensitive/partially sensitive) at ini-
tial screening. Access to the randomization lists
was under the control of a central administrator
(telephone/computer randomization). Patient en-
rollment commenced on 20 September 2007, and
continued until trial closure on 1 July 2008.
The primary endpoint of POTENT was time
to virologic failure using VL <50 copies/mL to de-
termine virologic response and VL ‡500 copies/mL
to define virologic rebound. The key secondary end-
point was treatment response at week 48. Other
secondary endpoints included (i) changes from
baseline in CD4+ cell count and viral load at each
study visit; and (ii) new clinical events indicating
AIDS progression or death.
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HIV VL was determined by the COBAS
AmpliPrep/COBAS TaqManHIV tests (Roche
Molecular Systems Inc, Branchburg, NJ, USA).
The baseline VLwas the geometric mean of the last
two pretreatment VL determinations. CD4+ cell
counts were assayed at the Covance Central
Laboratory Service (Princeton, NJ, USA). The
baseline CD4+ cell count was the mean of the last
two pretreatment measures. Baseline samples for
HIV genotyping were assayed in real-time using
the virco VirtualPhenotype method (VIRCO
Lab Inc, Titusville, NJ, USA).
Adverse events (AEs) were monitored through-
out the trial, were listed as non-serious or serious
in accordance with the pre-established study cri-
teria, and serious AEs were reported to the local
Clinical Monitor as soon as the study personnel
became aware of them.
Statistical Methods
As a result of the early termination of POTENT
due to poor patient enrollment, statistical tests
were not applied to the observational data that
were collected.
Results
Despite efforts to improve enrollment, including
amending the protocol to ease the entry criteria,
only 40 of the planned 800 patients (5%)
were randomized over an 8-month recruitment
period. Of the 40 patients who were randomized,
39 were treated. As a result of the slow enroll-
ment, the study was prematurely terminated
and only short-term data, from 39 weeks of ob-
servation, are available to provide observational
Assessed for eligibility (n = 147)
Excluded for various
reasons (n = 107)
Enrollment
Randomized (n = 40)
Allocated to TPV/r (n = 20)
• Received allocated intervention (n = 19)
• Did not receive allocated intervention
  (discontinued prior to treatment) [n = 1]
Lost to follow-up (n = 1)
Discontinued intervention due to:
• Other adverse event (n = 1)
• Consent withdrawn (n = 1)
• Lack of efficacy (n = 3)
• Premature trial termination (n = 13)
Analysed (n = 0)
• Excluded from analysis due to early
treatment discontinuation and early trial
termination (n = 19)
Analysed (n = 0)
• Excluded from analysis due to early
treatment discontinuation and early trial
termination (n = 20)
Allocated to DRV/r (n = 20)
• Received allocated intervention (n = 20)
• Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention due to:
• Other adverse event (n = 1)
• Consent withdrawn (n = 0)
• Lack of efficacy (n = 0)




Fig. 1. Patient disposition flow chart. DRV/r =darunavir/ritonavir; TPV/r = tipranavir/ritonavir.
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virologic and immunologic responses in these
patients.
Figure 1 presents the complete patient dis-
position results. Of the 39 patients who received
treatment, 19 were treated with TPV/r and 20
were treated with DRV/r. Seven patients were
prematurely discontinued from the trial, six in the
TPV/r arm and one in the DRV/r arm. Reasons
for discontinuation included AEs (n = 1 in each
group), lack of efficacy (n = 3, TPV/r group), lost
to follow-up (n = 1, TPV/r group), and with-
drawal of patient consent (n = 1, TPV/r group).
Of the six patients in the TPV/r group who inter-
rupted treatment, three were for loss of efficacy
when they experienced increased viral loads on
treatment, following initial drops on treatment.
Themean andmedian duration of treatment among
TPV/r and DRV/r patients was 15.3 and 13.0
weeks, respectively, with an overall range of
0.6–37.4 weeks.
The baseline demographics are presented in
table I. The mean age was 43.6 years, 82% were
male, and 77% were White. Their baseline hep-
atitis status included six patients who were co-
infected with hepatitis B or C: one patient in the
DRV/r group was hepatitis B surface antigen
(HBsAg) positive and five were HCV antibody
positive (three in the TPV/r and two in the DRV/r
groups). The mean baseline HIV RNA for all
patients in both arms was 3.9 log10 copies/mL and
the mean baseline CD4+ count was 283 cells/mm3
in the TPV/r arm versus 338 cells/mm3 in the
DRV/r arm. The mean time since HIV diagnosis
for all patients was 14.4 years. Nine patients in
the TPV/r group and 12 in the DRV/r group had
AIDS-related events (defined by the Centers for
Disease Control and Prevention, Atlanta, GA,
USA). The median number of prior ARV agents
was 11. No patient had prior maraviroc or ralte-
gravir exposure.
Of the newer drug classes, raltegravir was the
agent most commonly included in the OBR for
patients in both arms of the study (n = 14 and
n = 12, TPV/r and DRV/r groups, respectively).
Maraviroc was the next most common novel drug
included as part of OBR (n = 4 and n= 2, TPV/r
andDRV/r groups, respectively). Enfuvirtide was
included in the OBR of three patients in each arm
of the study. Resistance testing by virtual phe-
notypic analysis at baseline identified baseline
sensitivities to TPV/r and DRV/r (table II).
The most commonly reported AEs and clinical
laboratory abnormalities are listed in table III.
Drug-related AEs were experienced by 21%
and 25% of patients in the TPV/r and DRV/r
groups, respectively. One patient in each arm
experienced a drug-related AE that led to treat-
ment discontinuation.
Baseline sensitivities to TPV/r and DRV/r
were randomly distributed between the two
Table I. Patient baseline demographic data
TPV/r (n =19) DRV/r (n =20) Total (n= 39)
Sex [n (%)]
Male 15 (78.9) 17 (85.0) 32 (82.1)
Female 4 (21.1) 3 (15.0) 7 (17.9)
Ethnic origin [n (%)]
White 14 (73.7) 16 (80.0) 30 (76.9)
Black 5 (26.3) 1 (5.0) 6 (15.4)
Asian 0 (0) 3 (15.0) 3 (7.7)
BMI (kg/m2)
Mean –SD 24.9 – 4.3 23.3 – 3.0 24.0 – 3.7
Median (range) 24.8 (18.7–33.2) 23.3 (18.7–33.0) 23.8 (18.7–33.2)
Age (y)
Mean –SD 44.3 – 6.1 43.1 – 6.2 43.6 – 6.1
Median (range) 44.0 (33.0–53.0) 42.0 (34.0–63.0) 43.0 (33.0–63.0)
BMI = body mass index; DRV/r = darunavir/ritonavir; TPV/r = tipranavir/ritonavir.
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treatment arms, with 10 of 19 and 12 of 20 patient
isolates being sensitive to both TPV and DRV in
each treatment arm (TPV/r and DRV/r, respect-
ively).While there appeared to be some imbalance
between the arms in the number of patient isolates
that were TPV-partially sensitive/DRV-partially
sensitive (5 of 19 [26%] and 1 of 20 [5%], TPV/r
and DRV/r arms respectively), the total number
of patient isolates in each group were too small to
allow meaningful statistical analysis, limiting any
conclusions that might be drawn from these data.
The primary measures of therapeutic efficacy
in the POTENT trial were change in log10 VL and
change in CD4+ cell count from baseline values.
In the setting of ARV therapy, these virologic
and immunologic parameters are well established
as surrogate markers for viral replication activity
and relative immune health/reconstitution.[11,12]
In both study arms, patients experienced favor-
able changes in VL and CD4+ cell count from
baseline over the short-term course of treatment.
These observational trends were observed for
each study visit from week 2 through week 32
(note: only three patients in each arm had follow-
up data to week 32).
Observed log10 changes inVL (figure 2) indicated
a drop in VL >1.5 log10 copies/mL for both
treatment arms by week 2, with mean reductions
of ~2 log10 copies/mL by week 8, indicating short-
term potent virologic activity for both TPV/r- and
DRV/r-containing regimens in these treatment-
experienced patients. At no timepoint were the
changes in log10 HIV VL found to be different
between the two treatment groups.
Observed changes in CD4+ cell counts from
baseline (figure 3) showed similar increases in
both treatment arms over the period of treatment/
follow-up. By week 12, mean CD4+ counts rose
by 40–50 cells/mm3 in both arms. At no timepoint
were the changes in CD4+ cell counts from
baseline found to be different between the two
treatment groups.
Discussion
The POTENT trial was designed as a head-to-
head comparison of ritonavir-boosted TPV- versus
DRV-containing regimens in treatment-experienced
HIV-infected patients where the virus is resistant to
more than one PI. These two agents have not been
previously compared in a randomized clinical trial.
Limitations
Due to slow enrollment, only 39 patients were
randomized and received study drugs prior to
premature termination of the study. While data
Table II. Baseline sensitivities to tipranavir/ritonavir (TPV/r) and
darunavir/ritonavir (DRV/r)





ps = partially sensitive; s = sensitive.







Any 12 (63.2) 15 (75.0)
Serious 0 (0) 2 (10.0)
DAIDS G3 1 (5.3) 2 (10.0)
DAIDS G4 0 (0) 1 (5.0)
DR 4 (21.1) 5 (25.0)
DR leading to
discontinuation
1 (5.3) 1 (5.0)
Gastrointestinal 5 (26.3) 5 (25.0)
Hepatobiliary disorders 1 (5.3) 0 (0)
Laboratory abnormalities
DAIDS G3b 5 (26.3) 6 (30.0)
DAIDS G4c 0 (0) 4 (20.0)
a Unless associated with clinical symptoms, laboratory test
abnormalities were not reported as adverse events.
b Eleven patients had a total of 41 G3 laboratory abnormalities,
including changes in total cholesterol (n= 11), low-density
lipoprotein cholesterol (n= 14), creatine phosphokinase (n =4),
glucose (n= 4), triglycerides (n = 2), and amylase (n= 2).
c Four DAIDS G4 abnormalities were observed in the DRV/r arm,
none were seen in the TPV/r arm. One patient with G4 partial
thromboplastin time at visit 7, one patient with G4 INR and PT at
visit 4, and one patient with a G4 reduction in polymorphonuclear
neutrophils.
DAIDS =Division of AIDS; DR= drug related; DRV/r = darunavir/
ritonavir; G = grade; INR = International Normalized Ratio; PT = pro-
thrombin time; TPV/r = tipranavir/ritonavir.
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from the trial are insufficient to assess the primary
and secondary endpoints in a statistically rigorous
manner, they do provide observational data that
demonstrated short-term virologic and immuno-
logic benefits in highly treatment-experienced
patients initiating either TPV/r or DRV/r in com-
bination with an OBR.
Patients treated with a TPV/r- or DRV/r-
containing regimen experienced similar safety and
efficacy outcomes over the limited observation
period in this small cohort of triple-class-experi-
enced, HIV-infected patients who had previously
not responded to other PIs. However, it should be
noted that some of the clinical challenges with
TPV treatment include compliance due to higher
pill burden, and long-term side effects of this med-
ication, both of which were difficult to measure in
this study due to the low patient numbers, and the
limited follow-up period.
The novel integrase inhibitor raltegravir was
the most commonly used new agent in construct-
ing a new OBR in the POTENT trial. In a recent
subgroup analysis of a 48-week study[13] in treat-
ment-experienced patients with drug-resistantHIV,
raltegravir was compared with placebo, each arm
in combination with an OBR that included
TPV. In patients whose HIVwas sensitive to TPV
by genotypic or phenotypic assays, the combi-
nation of raltegravir plus TPV/r in the OBR
demonstrated ~30–33% better response rates
(HIV RNA <50 copies/mL at week 48) than pa-
tients taking placebo. In the same study, patients
who first used DRV in combination with ralte-
gravir demonstrated ~22% better response rate at
week 48 than the placebo group.[13] This long-
term improvement in virologic control demon-
strated the viability of regimens that combine
nonpeptidic PIs and novel class agents such as the
integrase inhibitors. In another recent study of
triple-class-experienced patients,[14] raltegravir in
combination with OBR was demonstrated to
have a robust and sustained antiviral effect through
96 weeks of treatment. Patients experienced mean
changes in VL of -1.6 and -1.38 log10 copies/mL
at 48 and 96 weeks, respectively. Additionally,
68% of patients had VLs <400 copies/mL and 55%
had <50 copies/mL at 48 weeks. At 96 weeks, 55%
and 48% of patients had VLs <400 copies/mL and
<50 copies/mL, respectively.
The observational data from the POTENT trial
demonstrated virologic and immunologic out-
comes that indicate successful treatment with
regimens containing TPV/r plus raltegravir. Both
treatment arms (TPV/r and DRV/r) demonstra-
ted good short-term efficacy and safety. The ob-
served changes from baseline in VL were similar







































Fig. 2. Changes in log10 viral load from baseline. Log10 HIV viral
loads were measured at each study visit (see Methods section), and
individual patient values were normalized to their corresponding
baseline (BL) values. Mean log10 declines for each treatment group
at each timepoint are depicted in the graph. The table at the bottom
presents the number of patients in each treatment arm at each
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Fig. 3. Changes in CD4+ cell counts from baseline. CD4+ cell
counts were measured at each study visit (see Methods section),
and individual patient values were normalized to their corresponding
baseline (BL) values. Mean CD4+ cell counts for each treatment
group at each timepoint are depicted in the graph. The table at the
bottom presents the number of patients in each treatment arm at each
timepoint. DRV/r= darunavir/ritonavir; TPV/r = tipranavir/ritonavir.
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achieved a VL <400 copies/mL, with all but
one patient (in the TPV/r arm) achieving a VL
<50 copies/mL. In addition, similar increases in
CD4+ cell counts were observed in both treatment
arms. Finally, the rates of serious AEs were sim-
ilar between the two arms (0% and 10% for TPV/r
and DRV/r, respectively). This information
supports current treatment guidelines and re-
emphasizes the clinical imperative of selecting
active, potent agents when attempting to con-
struct viable regimens in this patient population.
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